仑伐替尼联合卡瑞利珠单抗治疗无法手术的肝癌患者的疗效及对患者AFP、CEA、AFU的影响  

Efficacy of Lenvatinib Combined with Carrilizumab in Patients with Inoperable Liver Cancer and Influence on AFP,CEA and AFU

作　　者：蒋梦园 张明宵 史代萌 JIANG Mengyuan;ZHANG Mingxiao;SHI Daimeng(Nanyang First People's Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市第一人民医院,473000

出　　处：《实用癌症杂志》2025年第4期628-632,共5页The Practical Journal of Cancer

摘　　要：目的探究仑伐替尼联合卡瑞利珠单抗用于无法手术治疗的肝癌患者的疗效及对患者血清AFP、CEA、AFU的影响。方法收集145例无法手术治疗的肝癌患者病历资料进行研究。依照治疗方法的不同将患者进行分组,其中采用仑伐替尼+卡瑞利珠单抗治疗的作为观察组(78例),采用阿帕替尼+卡瑞利珠单抗治疗的作为对照组(67例)。2组均治疗3个周期。观察2组疗效、肿瘤标志物水平、血管新生相关指标水平及不良反应。结果2组客观缓解率(62.82%vs 46.27%)、疾病控制率(89.74%vs 76.12%)差异有统计学意义(χ^(2)=3.992,P=0.046;χ^(2)=4.844,P=0.028)。治疗前,2组AFP、CEA、AFU水平比较,差异无统计学意义(P>0.05);治疗后,2组各项指标水平均显著降低(P<0.001),且观察组低于对照组,差异有统计学意义(t=3.118,P=0.002;t=3.302,P=0.001;t=2.340,P=0.021)。治疗前,2组血管新生相关指标aFGF、bFGF、VEGF水平比较,差异无统计学意义(P>0.05);治疗后,2组各项指标水平均显著降低(P<0.001),且观察组低于对照组,差异有统计学意义(t=2.991,P=0.003、t=2.995,P=0.003、t=2.136,P=0.034)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论仑伐替尼与卡瑞利珠单抗联合使用不仅对无法手术治疗的肝癌患者的治疗效果有提升作用,而且能够降低患者血清肿瘤标志物水平及血管新生相关指标水平,且不良反应可控,安全性良好。Objective To explore the efficacy of lenvatinib combined with carrilizumab in patients with inoperable liver cancer and the effects on serum AFP,CEA and AFU.Methods The medical records of 145 patients with inoperable liver cancer were collected and studied.Patients were divided into the observation group(78 cases)treated with lenvatinib and carrilizumab,and the control group(67 cases)treated with apatinib and carrilizumab.Both groups were treated for 3 cycles.The therapeutic effect,tumor marker level,angiogenesis related index level and adverse reactions of the 2 groups were observed.Results The objective remission rate(62.82%vs 46.27%)and disease control rate(89.74%vs 76.12%)of the 2 groups had statistically significant difference(χ^(2)=3.992,P=0.046;χ^(2)=4.844,P=0.028).Before treatment,there was no significant difference in AFP,CEA and AFU levels between the 2 groups(P>0.05).After treatment,the levels of all indexes in the 2 groups were significantly decreased(P<0.001),and the observation group was lower than the control group,the difference was statistically significant(t=3.118,P=0.002;t=3.302,P=0.001;t=2.340,P=0.021).Before treatment,there was no significant difference in the levels of aFGF,bFGF and VEGF between the 2 groups(P>0.05).After treatment,the levels of all indexes in the 2 groups were significantly decreased(P<0.001),and the observation group was lower than the control group,with statistical significance(t=2.991,P=0.003,t=2.995,P=0.003,t=2.136,P=0.034).There was no significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion The combination of lenvatinib and carrelizumab can not only improve the therapeutic effect of inoperable liver cancer patients,but also reduce the level of tumor markers and angiogenesis related indicators,and the adverse reactions are controllable and safe.

关 键 词：仑伐替尼 卡瑞利珠单抗 无法手术 肝癌 疗效 

分 类 号：R735.7[医药卫生—肿瘤]